Clinical Trial Update: Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Bevacizumab/Tarceva and Tarceva/Sulindac in squamous cell carcinoma of the head and neck was terminated, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Avastin (bevacizumab)
• Sulindac (sulindac)
• Tarceva (erlotinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Status: TERMINATED | Results posted: 2017-03-14